Doublecortin-like kinase 2 (DCLK2) is a microtubule-associated protein belonging to the doublecortin (DCX) family, characterized by tandem doublecortin domains and a serine/threonine kinase domain. It shares structural homology with DCLK1 but differs in expression patterns and functional roles. DCLK2 is implicated in neuronal development, regulating microtubule dynamics critical for axon guidance, dendritic branching, and neuronal migration. Recent studies highlight its involvement in cancer progression, stem cell maintenance, and neurodegenerative disorders.
DCLK2 antibodies are essential tools for detecting DCLK2 expression and localization in tissues or cell lines. They enable research on its dual role as a structural regulator and signaling kinase, particularly in pathways like MAPK/ERK and Wnt/β-catenin. In cancer, DCLK2 overexpression correlates with tumor aggressiveness in pancreatic, colorectal, and ovarian cancers, making it a potential therapeutic target or biomarker. Antibodies against specific isoforms (e.g., full-length vs. truncated) help dissect their distinct functions. Challenges in antibody development include cross-reactivity with DCLK1 and distinguishing post-translational modifications. Validated DCLK2 antibodies support diagnostic assays, mechanistic studies, and preclinical drug evaluation, advancing understanding of its pathophysiological roles.